Sanofi CFO Jean-Baptiste de Chatillon (L) and CEO Paul Hudson (Romuald Meigneux/Sipa via AP Images)
March 16, 2023 04:10 PM EDTUpdated 04:24 PM
Pharma

Three­'s com­pa­ny: Sanofi fol­lows lead of Lil­ly and No­vo, slash­es in­sulin price by 78% and caps out-of-pock­et costs

Zachary Brennan

Senior Editor

Sanofi to­day joined with the oth­er two in­sulin jug­ger­nauts in the US to low­er the price of its best-sell­ing in­sulin prod­uct, Lan­tus (in­sulin glargine), by …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Bridge­Bio shares promis­ing re­sults in tri­al of Cana­van dis­ease gene ther­a­py

CRISPR ther­a­py re­duces swelling at­tacks by 81% in In­tel­lia fol­low-up study

Fac­ing lost re­bates, MGM Re­sorts to stop cov­er­ing GLP-1 weight loss shots

Ex­clu­sive: Uni­ver­si­ty of Toron­to spin­out rais­es $53.5M to cre­ate new obe­si­ty drugs with AI

Icon's quar­ter­ly earn­ings hit by biotech and phar­ma pull­back

sponsored

IDEAYA Bio­sciences: Tar­get­ing un­met mar­ket needs with pre­ci­sion on­col­o­gy

A service from the Financial Times